A Phase I, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent in Patients with Relapsed/Refractory Hematologic Malignancies
A Study of GFH009 in Patients With Hematologic Malignancies
Sponsor: GenFleet Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAT5785
U.S. Govt. ID: NCT04588922
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess the safety, effectiveness, pharmacokinetic (PK how long the drug is in your body and how it is metabolized) and pharmacodynamics (PD where does the drug go in your body and what is its biological effect) of the study drug, GFH009, in patients with relapsed or refractory hematologic malignancies including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or other lymphomas. This is the first time GFH009 is being studied in humans.
This study is closed
Andrew Lipsky, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with a hematologic malignancy (blood cancer)? Yes No
Do you have a history of HIV infection? Yes No
Do you have a history of chronic or current Hepatitis B or Hepatitis C infection? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator